Patients with type 1 diabetes (T1D) strive for keeping their blood sugar within narrow limits to reduce the risk of late diabetes complications. The downside of this strict glycemic control is an enhanced risk of developing severe hypoglycemia especially during sleep. Early prediction and prevention of hypoglycemia can improve long-term outcome for patients with diabetes. PreHypo will alert the user in advance using sophisticated but easy to use technology. The background for our technology have been published in medical journals, click here to read more.
Having a child with type 1 diabetes has large impact on a family. Type 1 diabetes requires daily injections of insulin and subsequent self-measurements of blood sugar to maintain well regulated blood sugar. Hypoglycemia is a feared condition for parents since it can result in brain damage, coma and in worst case even death of their child. Often parents to children diagnosed with Type 1 diabetes wake up several times during the night to check their child’s blood sugar level. However, not only during the night, but also when the child is at school or elsewhere the fear of sudden hypoglycemia is a grave concern. Our invention enable patient empowerment by triggering a customize and personalized alarm from the patients or relatives smartphone / smartwatch. This enables the patient, relatives or hospital staff to intervene by timely drinking or eating sugary fluids (juice) or food. After food intake the invention will detect the raising blood sugar and give a personalized feedback to the patient, relatives or hospital staff.
A condition where blood sugar falls below a critical level and disturb organ functions. It is often because of too much insulin combined with too little food intake. Low blood sugar (hypoglycemia) is the most common and most dangerous condition for many people with type 1 diabetes (T1D). Very low blood sugar may lead to insulin shock, which can be life threatening if not promptly treated. Recent reports have indicated that the incidence of hypoglycemia requiring emergency assistance is as high as 7.1% per year and that as many as 6-10% of all deaths in patients with T1D result from hypoglycemia. Patients with T1D are known to have increased risk of sudden, unexpected death during sleep. This phenomenon, known as “dead-in-bed syndrome,” occurs due to mechanisms that are poorly understood.
Our new invention makes prediction of hypoglycemia possible in people with diabetes. Emerging technologies such as the Continuous Glucose Monitoring (CGM), a device for live motoring of glucose levels have made it possible to follow the trend of glucose and possibly act in time before reaching alarming levels. Unfortunately, the precisions of these measurements are not always sufficient and reliable in detecting a forthcoming event of low glucose. We have developed a method using hidden information in the heart rhythm and combined it with information from the CGM device. This combination significantly improves the prediction of hypoglycemic events and thereby the possibility of a timely intervention.
Our sophisticated mathematical models predicts hypoglycemia up to 25 min. before it happens.
Our intellectual property is backed with new patented technology and equipment.
We use information from the autonomic nervous system hidden in recordings of the heart rhythm.
Our technology improve state of the art glucose monitoring, Continuous Glucose Monitoring (CGM). Alerts the patients to allow timely intervention by food intake.
We are a small team of dedicated people with background in biomedical engeneering, medicine, clinical research, and medical informatics.
PhD. Co-founder of Medicus Engineering and reQbo. Associate Professor, arhus University, Health. Expert in development of point-of-care devices in health care.
MD, DMSc, Professor of Experimental cardiac Surgery. More than 20 years of experience with telemedicine and behind several inventions being acquired by global players.
CEO, board member and cofounder of several biotech and medtech companies n Denmark;amongst others Cetrea, CLC Bio, Action Pharma and PNN Medical.
MSc, PhD student. Consultant for Medicus Engineering. Expert in patternrecognition techniques.
MSc. Business Development consultant for Medicus Engineering. Over 15 years expertise as technology sourcing expert, and business manager from several medtech and pharma companies amongst others Coloplast, Novo Nordisk and LEO Pharma.
To implement our hypoglycemic prediction technology in clinical practice preferably in collaboration with larger industrial players.
We have proven the power of our technology which has been tested in both clinical setting and during daily living. We are currently setting up new clinical trials to test and further validate our technology.
We are always open for new partners